Table 1.

Baseline characteristics of KTRs explored

Baseline CharacteristicsKTRs, n=45
Age, yr63.5±16.3
Sex (M/W), n23/22
Diabetes mellitus, n (%)10 (22.2)
Hypertension, n (%)36 (80)
BMI, kg/m226.2±4.7
Time from transplantation, yr
 Median (range)6.9 (0.22–30.2)
Immunized KTR, n (%)12 (26.7)
 Median PRA class I6
 Median PRA class II14.5
Previous history of rejection, n (%)1 (2.2)
eGFR, ml/min per 1.73 m243.3±15.7
P/C ratio, g/g0.26±0.06
Lymphocytes count, per mm3
 CD3+892±476
 CD4+447±263
 CD8+397±297
Induction therapy for KT, n (%)
 ATG18 (40)
 Anti–R-IL227 (60)
IS regimen, n (%)
 Tacrolimus24 (53.3)
 Cyclosporin8 (17.8)
 MMF37 (82.2)
 AZA4 (8.9)
 Everolimus3 (6.7)
 Belatacept10 (22.2)
 Steroids21 (46.7)
  • M, men; W, women; BMI, body mass index; PRA, panel reactive antibodies; P/C, proteinuria/creatininuria; KT, kidney transplantation; ATG, antithymoglobuline; R-IL2, IL-2 receptor; IS, immunosuppressive; MMF, mycophenolate mofetil; AZA, azathioprine.